Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/65144

Type
Article
Copyright
Open access
Collections
Share

Statistics
Metadata
Show full item record

THE EFFECT OF PREVIOUS SARS-COV-2 INFECTION ON SYSTEMIC IMMUNE RESPONSES IN INDIVIDUALS WITH TUBERCULOSIS
Xavier, Mariana Simao et al. | Date Issued: 2024
Author
Xavier, Mariana Simao
Pereira, Mariana Araújo
Oliveira, Quézia Medeiros de
Sant'Anna, Flávia Marinho
Ridolfi, Felipe Moreira
Andrade, Alice Motta Soares de
Figueiredo, Marina C.
Sterling, Timothy R.
Gordhan, Bhavna G.
Kana, Bavesh D.
Andrade, Bruno de Bezerril
Rolla, Valeria Cavalcanti
Silva, Adriano Gomes da
Affilliation
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Programa de Pós-Graduação em Pesquisa Clínica em Doenças Infecciosas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Pesquisa Clínica e Translacional. Salvador, BA, Brasil / Faculdade ZARNS. Curso de Medicina. Salvador, BA, Brasil / Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Micobacterioses. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Micobacterioses. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Micobacterioses. Rio de Janeiro, RJ, Brasil.
Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative. Salvador, BA, Brasil.
Vanderbilt University Medical Center. Department of Medicine. Division of Infectious Diseases. Nashville, TN, USA.
Vanderbilt University Medical Center. Department of Medicine. Division of Infectious Diseases. Nashville, TN, USA.
University of the Witwatersrand. National Health Laboratory Service. Faculty of Health Sciences. School of Pathology. Centre of Excellence for Biomedical Tuberculosis Research. National Research Foundation. Department of Science and Innovation. Johannesburg, South Africa.
University of the Witwatersrand. National Health Laboratory Service. Faculty of Health Sciences. School of Pathology. Centre of Excellence for Biomedical Tuberculosis Research. National Research Foundation. Department of Science and Innovation. Johannesburg, South Africa.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Pesquisa Clínica e Translacional. Salvador, BA, Brasil / Faculdade ZARNS. Curso de Medicina. Salvador, BA, Brasil / Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Micobacterioses. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Micobacterioses. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório Interdisciplinar de Pesquisas Médicas. Rio de Janeiro, RJ, Brasil.
Abstract
Background: The impact of previous SARS-CoV-2 infection on the systemic immune response during tuberculosis (TB) disease has not been explored. Methods: An observational, cross-sectional cohort was established to evaluate the systemic immune response in persons with pulmonary tuberculosis with or without previous SARS-CoV-2 infection. Those participants were recruited in an outpatient referral clinic in Rio de Janeiro, Brazil. TB was defined as a positive Xpert-MTB/RIF Ultra and/or a positive culture of Mycobacterium tuberculosis from sputum. Stored plasma was used to perform specific serology to identify previous SARS-CoV-2 infection (TB/Prex-SCoV-2 group) and confirm the non- infection of the tuberculosis group (TB group). Plasmatic cytokine/chemokine/growth factor profiling was performed using Luminex technology. Tuberculosis severity was assessed by clinical and laboratory parameters. Participants from TB group (4.55%) and TB/Prex-SCoV-2 (0.00%) received the complete COVID-19 vaccination. Results: Among 35 participants with pulmonary TB, 22 were classified as TB/Prex-SCoV-2. The parameters associated with TB severity, together with hematologic and biochemical data were similar between the TB and TB/Prex-SCoV-2 groups. Among the signs and symptoms, fever and dyspnea were significantly more frequent in the TB group than the TB/Prex-SCoV-2 group (p < 0,05). A signature based on lower amount of plasma EGF, G-CSF, GM-CSF, IFN-α2, IL-12(p70), IL-13, IL-15, IL-17, IL-1β, IL-5, IL-7, and TNF-β was observed in the TB/Prex-SCoV-2 group. In contrast, MIP-1β was significantly higher in the TB/Prex-SCoV-2 group than the TB group. Conclusion: TB patients previously infected with SARS-CoV-2 had an immunomodulation that was associated with lower plasma concentrations of soluble factors associated with systemic inflammation. This signature was associated with a lower frequency of symptoms such as fever and dyspnea but did not reflect significant differences in TB severity parameters observed at baseline.
Keywords
Tuberculosis
SARS-CoV-2
Immune response
Previous infection
Disease severity
Immunomodulation
 
Publisher
Frontiers Media
Citation
XAVIER, Mariana Simao et al. The effect of previous SARS-CoV-2 infection on systemic immune responses in individuals with tuberculosis. Frontiers in Immunology, v. 15, p. 1-11, 27 June 2024.
DOI
10.3389/fimmu.2024.1357360
ISSN
1664-3224
Notes
Produção científica do Laboratório Interdisciplinar de Pesquisas Médicas.